Showing results (31-40 of 776) with videos related to
Sort By:
Pageof 78
Blood Cancer Journal|September 8, 2018
The biological significance of histone modifiers in multiple myeloma: clinical applicationsHiroto Ohguchi, Teru Hideshima, Kenneth C AndersonReviews in Clinical and Experimental Hematology|March 6, 2003
Novel biologically based therapeutic strategies in myelomaDeepak Gupta, Teru Hideshima, Kenneth C AndersonExpert Review of Anticancer Therapy|October 6, 2006
Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaNoopur Raje, Teru Hideshima, Kenneth C AndersonExperimental Hematology|June 30, 2015
Novel therapeutic strategies for multiple myelomaNaoya Mimura, Teru Hideshima, Kenneth C AndersonImmunological Reviews|July 9, 2003
Novel therapeutic approaches for multiple myelomaTeru Hideshima, Paul Richardson, Kenneth C AndersonHematology/Oncology Clinics of North America|November 13, 2007
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapiesConstantine S Mitsiades, Douglas W McMillin, Steffen Klippel, et al.Molecular Cancer Therapeutics|December 21, 2002
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.Oncogene|December 4, 2003
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell linesTeru Hideshima, Toshiaki Hayashi, Dharminder Chauhan, et al.Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.Pageof 78